Long transport times to its production hub in Kalundborg has led to the Danish pharmaceutical giant Novo Nordisk investing 12 billion kroner in a new production facility in Clayton in the US state of North Carolina.
Novo Nordisk underlined that the move was down to infrastructural issues and that the new factory would generate 700 jobs in the US.
“We decided to place the new API facilities in the US for strategic reasons,” said Henrik Wulff, the executive vice president and head of product supply at Novo Nordisk.
“The US is by far our largest market and there are many logistical and economic advantages of having a larger part of our manufacturing in our main market. After a thorough evaluation of multiple sites and an extensive vetting process, Clayton ended up being our preferred location.”
READ MORE: Novo Nordisk reveals staggering interim profits
Måløv facility
According to Wulff, the company looked at locations in Asia, Denmark and the east coast of the US before deciding on Clayton.
The company already has a strong a presence in Clayton as it has had a filling, packaging and prefilled device manufacturing facility in the city for close to 20 years now. The new facility is expected to be operational sometime during 2020.
Novo Nordisk also revealed it could be building a new 1 billion kroner facility in Måløv, located northwest of Copenhagen.
